Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by Mbxwatcheron Dec 22, 2022 2:44pm
146 Views
Post# 35187746

RE:There is no way…

RE:There is no way…100 %

I really felt that Cameron did everything he could to telegraph this result in the last webcast with Adelaide Capital, so in fact it is entirely unsurprising today.

The only real surprise is VTM being absolutely zero in the quarter.

Honestly, 9 months ago did anyone see that coming?

They knew it was bad enough to tease Kinlytic,  AGAIN

QAPS and Antigen are both headed in the right direction, but what is the future for VTM?

Dont we have a whole building dedicated to it?

There is going to be time to acquire at lower numbers I'm afraid....

Happy holidays to all, and thanks again for all the constructive dialogue over the year.  Always good to look at it objectively, and as stated earlier will begin acquiring again in the new year.
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse